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INTRODUCTION 
                          AIDS was first recognized in the United States in the 
summer of 1981, when the U.S. Centers for Disease Control and Prevention 
(CDC) reported the unexplained occurrence of Pneumocystis jiroveci 
(formerly P. carinii) pneumonia in five previously healthy homosexual men 
in Los Angeles and of Kaposi's sarcoma (KS) with or without P. jiroveci 
pneumonia in 26 previously healthy homosexual men in New York and Los 
Angeles. Within months, the disease became recognized in male and female 
injection drug users (IDUs) and soon thereafter in recipients of blood 
transfusions and in hemophiliacs. As the epidemiologic pattern of the 
disease unfolded, it became clear that an infectious agent transmissible by 
sexual (homosexual and heterosexual) contact and blood or blood products 
was the most likely etiologic cause of the epidemic1. 
                       In 1983, human immunodeficiency virus (HIV) was isolated 
from a patient with lymphadenopathy, and by 1984 it was demonstrated 
clearly to be the causative agent of AIDS. In 1985, a sensitive enzyme-
linked immunosorbent assay (ELISA) was developed, which led to an 
appreciation of the scope and evolution of the HIV epidemic at first in the 
United States and other developed nations and ultimately among developing 
nations throughout the world 1. 
              Luc Montaineger from Pasteur Institute, France, discovered the 
causative agent in 1983,and labelled it as LAV -2 lymphadenopathy 
associated virus.[2]. Robert Gallo from USA  also isolated the virus in 1984, 
and named it HTLV-III, Human T Lymphotropic Virus-III. The 
International committee on Taxonomy of Viruses re designated both the 
viruses and named it as Human Immunodeficiency Virus. 
 
                                     Acquired immunodeficiency syndrome (AIDS) is 
caused by human immunodeficiency virus (HIV) which can be contracted 
through sexual contact, exposure to blood including sharing contaminated 
needles and syringes and by certain blood products or other body fluids. 
Human immunodeficiency virus/acquired immunodeficiency syndrome has 
been the leading cause of death among young adults in the United state and 
has a devastating impact on people in the developing countries2. The clinical 
presentation of this disease include pneumonia, fever/pyrexia loss of vision, 
night sweats, chronic diarrhoea, weight loss, lymphadenopathy, cough, and 
itchy maculopapular generalized skin rash, blue discolouration, anaemia and 
hairy leukoplakia. 3,4,5,6 
              Worldwide there are an estimated 33 million persons infected with 
HIV. In Central and East Africa in some urban areas, as many as one-third 
of sexually active adults are infected. HIV infection began to spread in Asia 
in the late 1980s. The most common mode of transmission is bidirectional 
heterosexual spread. The reason for the greater risk for transmission with 
heterosexual intercourse in Africa and Asia than in the United States may 
relate to cofactors such as general health status, the presence of genital 
ulcers, relative lack of male circumcision, the number of sexual partners, and 
different HIV serotypes7. 
Incidence in India 
 
                      In 2006, the Joint United Nations Program on HIV/AIDS 
(UNAIDS) and the World Health Organization (WHO) estimated that 5.7 
million people in India were infected with the human immunodeficiency 
virus (HIV), a figure that captured wide attention and raised the possibility 
that India had more infected people than any other country10.In 2007, 
however, the estimate was revised downward to 2.5 million (range, 2.0 
million to 3.1 million) - a revision so large that it reduced by nearly 10%10 . 
 
                               The staggering worldwide evolution of the HIV 
pandemic has been matched by an explosion of information in the areas of 
HIV virology, pathogenesis (both immunologic and virologic), treatment of 
HIV disease, treatment and prophylaxis of the opportunistic diseases 
associated with HIV infection, prevention of infection, and vaccine 
development. The information flow related to HIV disease is enormous and 
continues to expand, and it has become almost impossible for the health care 
generalist to stay abreast of the literature. The purpose of this study is to 
present the prevalence of the electrolyte disturbances among HIV-infected 
patients admitted in medicine and STD Dept.’s, Govt. Rajaji Hospital, 
Madurai. 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURES 
Etiologic Agent 
                           The etiologic agent of AIDS is HIV, which belongs to the 
family of human retroviruses (Retroviridae) and the subfamily of 
lentiviruses.. The four recognized human retroviruses belong to two distinct 
groups: the human T lymphotropic viruses (HTLV)-I and HTLV-II, which 
are transforming retroviruses; and the human immunodeficiency viruses, 
HIV-1 and HIV-2, which cause cytopathic effects either directly or 
indirectly. The most common cause of HIV disease throughout the world, 
and certainly in the United States, is HIV-1, which comprises several 
subtypes with different geographic distributions. HIV-2 was first identified 
in 1986 in West African patients and was originally confined to West Africa. 
However, a number of cases that can be traced to West Africa or to sexual 
contacts with West Africans have been identified throughout the world. Both 
HIV-1 and HIV-2 are zoonotic infections. The Pan troglodytes troglodytes 
species of chimpanzees has been established as the natural reservoir of HIV-
1 and the most likely source of original human infection. HIV-2 is more 
closely related phylogenetically to the simian immunodeficiency virus (SIV) 
found in sooty mangabeys than it is to HIV-11. 
                        The modes of transmission of HIV are similar to those of 
hepatitis B, in particular with respect to sexual, parenteral, and vertical 
transmission. Although certain sexual practices (eg, receptive anal 
intercourse) are significantly riskier than other sexual practices (eg, oral 
sex), it is difficult to quantify per-contact risks. The reason is that studies of 
sexual transmission of HIV show that most people at risk for HIV infection 
engage in a variety of sexual practices and have sex with multiple persons, 
only some of whom may actually be HIV infected. Thus, it is difficult to 
determine which practice with which person actually resulted in HIV 
transmission7. 
                         Nonetheless, the best available estimates indicate that the 
risk of HIV transmission with receptive anal intercourse is between 1:100 
and 1:30, with insertive anal intercourse 1:1000, with receptive vaginal 
intercourse 1:1000, with insertive vaginal intercourse 1:10,000, and with 
receptive fellatio with ejaculation 1:1000. The per-contact risk of HIV 
transmission with other behaviors, including receptive fellatio without 
ejaculation, insertive fellatio, and cunnilingus, is not known7. 
                       All per-contact risk estimates assume that the source is HIV 
infected. If the HIV status of the source is unknown, the risk of transmission 
is the risk of transmission multiplied by the probability that the source is 
HIV infected. This would vary by risk practices, age, and geographic area. A 
number of cofactors are known to increase the risk of HIV transmission 
during a given encounter, including the presence of ulcerative or 
inflammatory sexually transmitted diseases, trauma, menses, and lack of 
male circumcision7. 
                             The risk of acquiring HIV infection from a needlestick 
with infected blood is approximately 1:300. Factors known to increase the 
risk of transmission include depth of penetration, hollow bore needles, 
visible blood on the needle, and advanced stage of disease in the source. The 
risk of HIV transmission from a mucosal splash with infected blood is 
unknown but is assumed to be significantly lower7. 
                    The risk of acquiring HIV infection from illicit drug use with 
sharing of needles from an HIV-infected source is estimated to be 1:150. 
Use of clean needles markedly decreases the chance of HIV transmission but 
does not eliminate it if other drug paraphernalia are shared (eg, cookers)7,8.  
When blood transfusion from an HIV-infected donor occurs, the risk of 
transmission is 95%. Fortunately, since 1985, blood donor screening using 
the HIV enzyme-linked immunosorbent assay (ELISA) has been universally 
practiced in the United States. Also, persons who have recently engaged in 
unsafe behaviors (eg, sex with a person at risk for HIV, injection drug use) 
are not allowed to donate. This eliminates donations from persons who are 
HIV infected but have not yet developed antibodies (ie, persons in the 
"window" period). In recent years, HIV antigen and viral load testing have 
been added to the screening of blood to further lower the chance of HIV 
transmission. With these precautions, the chance of HIV transmission with 
receipt of blood transfusion is about 1:1,000,0007. 
                           In the absence of perinatal HIV prophylaxis, between 13% 
and 40% of children born to HIV-infected mothers contract HIV infection. 
The risk is higher with vaginal than with cesarean delivery, higher among 
mothers with high viral loads, and higher among those who breast-feed their 
children. The risk can be decreased by administering antiretroviral treatment 
to the mother during pregnancy and to the infant immediately after birth7,9. 
HIV has not been shown to be transmitted by respiratory droplet spread, by 
vectors such as mosquitoes, or by casual nonsexual contact7. 
 
                  In general, the progression of HIV-related illness is similar in 
men and women. However, there are some important differences. Women 
seek medical attention later than men. They are at risk for gynecologic 
complications of HIV, including recurrent candidal vaginitis, pelvic 
inflammatory disease, and cervical dysplasia. Violence directed against 
women, pregnancy, and frequent occurrence of drug use and poverty all 
complicate the treatment of HIV-infected women7.  
                      
CLINICAL MANIFESTATIONS1 
    The clinical consequences of HIV infection encompass a spectrum 
ranging from an acute syndrome associated with primary infection to a 
prolonged asymptomatic state to advanced disease. 
THE ACUTE HIV SYNDROME1: 
       The acute phase represents the initial response of an immunocompetent 
adult to HIV infection. Clinically, this is typically a self-limited illness that 
develops in 50% to 70% of adults 3 to 6 weeks after infection; it is 
characterized by nonspecific symptoms including sore throat, myalgia, fever, 
rash, and sometimes aseptic meningitis. 
The Asymptomatic Stage—Clinical Latency1 
Although the length of time from initial infection to the development of 
clinical disease varies greatly, the median time for untreated patients is ~10 
years. HIV disease with active virus replication is ongoing and progressive 
during this asymptomatic period.  
       The middle, chronic phase represents a stage of relative containment of 
the virus. The immune system is largely intact at this point, but there is 
continued HIV replication that may last for several years. Patients either are 
asymptomatic or develop persistent lymphadenopathy, and many patients 
have "minor" opportunistic infections such as thrush (Candida) or herpes 
zoster. During this phase, viral replication in the lymphoid tissues continues 
unabated. The extensive viral turnover is associated with continued loss of 
CD4+ cells, but a large proportion of the CD4+ cells is replenished and the 
decline of CD4+ cells in the peripheral blood is modest 
Symptomatic Disease1 
                The final, crisis phase is characterized by a catastrophic 
breakdown of host defenses, a marked increase in viremia, and clinical 
disease. Typically, patients present with fever of more than 1 month's 
duration, fatigue, weight loss, and diarrhea; the CD4+ cell count is reduced 
below 500 cells/µL. After a variable interval, patients develop serious 
opportunistic infections, secondary neoplasms, and/or neurologic 
manifestations (so-called AIDS-defining conditions), and the patient is said 
to have full-blown AIDS 
             A diagnosis of AIDS is made in anyone with HIV infection and a 
CD4+ T cell count <200/µL and in anyone with HIV infection who develops 
one of the HIV-associated diseases considered to be indicative of a severe 
defect in cell-mediated immunity . 
 
Clinical Categories of HIV Infection1 
Category A: 
 Consists of one or more of the conditions listed below in an adolescent or 
adult (>13 years) with documented HIV infection. Conditions listed in 
categories B and C must not have occurred.  
Asymptomatic HIV infection  
Persistent generalized lymphadenopathy  
Acute (primary) HIV infection with accompanying illness or history of acute 
HIV infection 
 
Category B:  
                   It consists of symptomatic conditions in an HIV-infected 
adolescent or adult that are not included among conditions listed in clinical 
category C and that meet at least one of the following criteria:  
(1) The conditions are attributed to HIV infection or are indicative of a 
defect in cell-mediated immunity; or 
 (2) the conditions are considered by physicians to have a clinical course or 
to require management that is complicated by HIV infection. Examples 
include, but are not limited to, the following:  
Bacillary angiomatosis  
Candidiasis, oropharyngeal (thrush)  
Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to 
therapy  
Cervical dysplasia (moderate or severe)/cervical carcinoma in situ  
Constitutional symptoms, such as fever (38.5°C) or diarrhea lasting >1 
month  
Hairy leukoplakia, oral  
Herpes zoster (shingles), involving at least two distinct episodes or more 
than one dermatome  
Idiopathic thrombocytopenic purpura  
Listeriosis  
Pelvic inflammatory disease, particularly if complicated by tuboovarian 
abscess  
Peripheral neuropathy 
Category C:  
Conditions listed in the AIDS surveillance case definition.  
Candidiasis of bronchi, trachea, or lungs  
Candidiasis, esophageal  
Cervical cancer, invasive  
Coccidioidomycosis, disseminated or extrapulmonary  
Cryptococcosis, extrapulmonary  
Cryptosporidiosis, chronic intestinal (>1 month's duration)  
Cytomegalovirus disease (other than liver, spleen, or nodes)  
Cytomegalovirus retinitis (with loss of vision)  
Encephalopathy, HIV-related  
Herpes simplex: chronic ulcer(s) (>1 month's duration); or bronchitis, 
pneumonia, or esophagitis  
Histoplasmosis, disseminated or extrapulmonary  
Isosporiasis, chronic intestinal (>1 month's duration)  
Kaposi's sarcoma  
Lymphoma, Burkitt's (or equivalent term)  
Lymphoma, primary, of brain  
Mycobacterium avium complex or M. kansasii, disseminated or 
extrapulmonary  
Mycobacterium tuberculosis, any site (pulmonarya or extrapulmonary)  
Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary  
Pneumocystis jiroveci pneumonia  
Pneumonia, recurrenta  
Progressive multifocal leukoencephalopathy  
Salmonella septicemia, recurrent  
Toxoplasmosis of brain  
Wasting syndrome due to HIV  
 
 
 
Diagnosis and Laboratory Monitoring of HIV Infection11 
         The establishment of HIV as the causative agent of AIDS and related 
syndromes early in 1984 was followed by the rapid development of sensitive 
screening tests for HIV infection. By March 1985, blood donors in the 
United States were routinely screened for antibodies to HIV. In June 1996, 
blood banks in the United States added the p24 antigen capture assay to the 
screening process to help identify the rare infected individuals who were 
donating blood in the time (up to 3 months) between infection and the 
development of antibodies. In 2002 the ability to detect early infection with 
HIV was further enhanced by the licensure of nucleic acid testing (NAT) as 
a routine part of blood donor screening.  
DIAGNOSIS OF HIV INFECTION 
         The CDC has recommended that screening for HIV infection be 
performed as a matter of routine health care. The diagnosis of HIV infection 
depends upon the demonstration of antibodies to HIV and/or the direct 
detection of HIV or one of its components. As noted above, antibodies to 
HIV generally appear in the circulation 2–12 weeks following infection. 
 
ANTIBODY DETECTION BY ELISA/EIA : 
             This is the most widely used screening method. It has a sensitivity of 
> 99.5 %.  Hence the false positivity is also present  with conditions such as 
influenza vaccination, hepatic disease auto antibodies. Direct solid phase 
anti globulin ELISA is the most commonly used method. Antigen obtained 
from cell cultures and recombinant techniques represents all subtypes of 
both  HIV 1 and HIV 2. The antigen is coated on micro titre wells and test 
serum is added to it. If antibody to HIV is present in the serum it binds to the 
antigen. After washing away the unbound serum anti human 
immunoglobulin bound to an enzyme is added, followed by a colour forming 
substrate. If the test serum contains anti HIV antibody then a photo 
metrically detectable colour is formed and can be read by a special ELISA 
reader. 
                  The first generation ELISA tests detect the anti HIV- 1 antibodies 
of Ig G type using  antigens derived from  virus grown in cell cultures. 
The second generation ELISA tests detect the anti HIV  -  1 and anti HIV – 2 
antibodies using recombinant antigens. 
      Third generation ELISA tests detect Ig M antibodies using synthetic 
oligo peptides. 
      The fourth generation ELISA tests combine detection of antibodies to 
HIV with detection of the p24 antigen of HIV. Hence more helpful in 
identifying individuals with infection during the window period. 
              Screening is performed with an enzyme-linked immunosorbent 
assay (ELISA). The current HIV test used in the United States is a 
combination HIV-1/HIV-2 enzyme immunoassay test kit that is also 
sensitive to antibodies to HIV-2. The Centers for Disease Control and 
Prevention offer special tests for HIV-2 and HIV-1 non-B subtypes. 
           A positive screening test is confirmed by a repeat positive ELISA 
and a positive Western blot (presence of at least two of the following bands: 
p24, gp41, gp120/160). 
           An isolated positive ELISA result should not be reported to the 
patient until this result is confirmed by a Western blot. An indeterminate test 
is one for which the ELISA is positive but the criteria for a positive Western 
blot are not fulfilled. A rapid HIV-1 antibody test has been approved by the 
U.S. Food and Drug Administration and can be considered for use outside of 
traditional laboratory and clinical settings. 
 
WESTERN BLOT 
        The most commonly used confirmatory test is the Western blot . This 
assay takes advantage of the fact that multiple HIV antigens of 
different,well-characterized molecular weights elicit the production of 
specific antibodies. These antigens can be separated on the basis of 
molecular weight, and antibodies to each component can be detected as 
discrete bands on the Western blot. A negative Western blot is one in which 
no bands are present at molecular weights corresponding to HIV gene 
products. In a patient with a positive or indeterminate EIA and a negative 
Western blot, one can conclude with certainty that the EIA reactivity was a 
false positive. On the other hand, a Western blot demonstrating antibodies to 
products of all three of the major genes of HIV (gag, pol, and env) is 
conclusive evidence of infection with HIV. Criteria established by the U.S. 
Food & Drug Administration (FDA) in 1993 for a positive Western blot 
state that a result is considered positive if antibodies exist to two of the three 
HIV proteins: p24, gp41, and gp120/160. 
 
          Complete blood count (CBC), routine chemistry 
     The CD4+ T cell count is the laboratory test generally accepted as the 
best indicator of the immediate state of immunologic competence of the 
patient with HIV infection. This measurement, which can be made directly 
or calculated as the product of the percent of CD4+ T cells (determined by 
flow cytometry) and the total lymphocyte count [determined by the white 
blood cell count (WBC) and the differential percent], has been shown to 
correlate very well with the level of immunologic competence.  
            Patients with CD4+ T cell counts <200/microL are at high risk of 
disease from P. jiroveci, while patients with CD4+ T cell counts <50/microL 
are at high risk of disease from CMV, mycobacteria of the M. avium 
complex (MAC) and/or T. gondii .  
       Patients with HIV infection should have CD4+ T cell measurements 
performed at the time of diagnosis and every 3–6 months thereafter. More 
frequent measurements should be made if a declining trend is noted.  
According to most guidelines, a CD4 T cell count <350/microL is an 
indication for consideration of initiating ARV therapy, and a decline in 
CD4+ T cell count of >25% is an indication for considering a change in 
therapy.  
      Once the CD4+ T cell count is <200/microL, patients should be placed 
on a regimen for P.jiroveci prophylaxis, and once the count is <50/microL, 
primary prophylaxis for MAC infection is indicated. As with any laboratory 
measurement, one may wish to obtain two determinations prior to any 
significant changes in patient management based upon CD4+ T cell count 
alone.  
         In patients with hypersplenism or who have undergone splenectomy 
the CD4+ T cell percentage may be a more reliable indication of immune 
function than the CD4+ T cell count. A CD4+ T cell percent of 15 is 
comparable to a CD4+ T cell count of 200/µL. 
HIV RNA DETERMINATIONS 
         Facilitated by highly sensitive techniques for the precise quantitation 
of small amounts of nucleic acids, the measurement of serum or plasma 
levels of HIV RNA has become an essential component in the monitoring of 
patients with HIV infection. As discussed under diagnosis of HIV infection, 
the two most commonly used techniques are the RT-PCR assay and the 
bDNA assay. By utilizing more sensitive, nested PCR techniques and by 
studying tissue levels of virus as well as plasma levels, HIV RNA can be 
detected in virtually every patient with HIV infection. HIV RNA 
measurements are greatly influenced by the state of activation of the immune 
system and may fluctuate greatly in the setting of secondary infections or 
immunization. For these reasons, decisions based upon HIV RNA levels 
should never be made on a single determination. Measurements of plasma 
HIV RNA levels should be made at the time of HIV diagnosis and every 3–6 
months thereafter in the untreated patient. In general, most guidelines 
suggest that therapy be considered in patients with >100,000 copies of HIV 
RNA per milliliter. 
             HIV RNA measurements are to be done frequently to monitor 
therapy,which  pose economic burden to  many people in developing 
countries.Hence the need other simple clinical or laboratory parameter to 
monitor therapy is essential in developing countries. 
HIV RESISTANCE TESTING 
         The availability of multiple ARV drugs as treatment options has 
generated a great deal of interest in the potential for measuring the 
sensitivity of an individual's HIV virus(es) to different ARV agents. HIV 
resistance testing can be done through either genotypic or phenotypic 
measurement 
CO-RECEPTOR TROPISM ASSAYS 
              Two commercial assays; the Trofile assay (Monogram Biosciences) 
and the Phenoscript assay (VIRalliance), are available to make this 
determination. These assays clone the envelope regions of the patient's virus 
into an indicator virus that is then used to infect target cells expressing either 
CCR5 or CXCR4 as their co-receptor. These assays take weeks to perform 
and are expensive. 
         Tuberculin skin test 
          Rapid plasma reagin (RPR) test 
         Toxoplasma and cytomegalovirus (CMV) immunoglobin (Ig) G and 
hepatitis A, B (HBsAg, HBsAb, HBcAb), and C serologie 
        Chlamydia/gonococcal urine/cervical probe          
 Cervical Papanicolaou smear (most commonly using the thin prep 
method) 
 HIV resistance testing at baseline, with treatment failure, and 
particularly for pregnant women  
 
Sodium Balance 
                      Sodium is actively pumped out of cells by the Na+, K+-ATPase 
pump. As a result, 85–90% of all Na+ is extracellular, and the ECF volume is 
a reflection of total body Na+ content. Normal volume regulatory 
mechanisms ensure that Na+ loss balances Na+ gain. If this does not occur, 
conditions of Na+ excess or deficit ensue and are manifest as edematous or 
hypovolemic states, respectively. It is important to distinguish between 
disorders of osmoregulation and disorders of volume regulation since water 
and Na+ balance are regulated independently. Changes in Na+ concentration 
generally reflect disturbed water homeostasis, whereas alterations in Na+ 
content are manifest as ECF volume contraction or expansion and imply 
abnormal Na+ balance12.  
Hyponatremia 
            A plasma Na+ concentration <135 mmol/L usually reflects a 
hypotonic state 12 
Symptoms and Signs: 
                                    Whether hyponatremia is symptomatic depends on its 
severity and acuity. Chronic disease can be severe (sodium concentration 
less than 110 mEq/L), yet remarkably asymptomatic because the brain has 
adapted by decreasing its tonicity over weeks to months. Acute disease that 
has developed over hours to days can be severely symptomatic with 
relatively moderate hyponatremia. Mild hyponatremia (sodium 
concentrations of 130–135 mEq/L) is usually asymptomatic13. 
               Mild symptoms of nausea and malaise progress to headache, 
lethargy, and disorientation as the sodium concentration drops. The most 
serious symptoms are respiratory arrest, seizure, coma, permanent brain 
damage, brainstem herniation, and death. Premenopausal women are much 
more likely than menopausal women to die or suffer permanent brain injury 
from hyponatremic encephalopathy, suggesting a hormonal role in the 
pathophysiology13,14. 
Potassium Balance 
                          Potassium is the major intracellular cation. The normal 
plasma K+ concentration is 3.5–5.0 mmol/L, whereas that inside cells is 
about 150 mmol/L. Therefore, the amount of K+ in the ECF (30–70 mmol) 
constitutes <2% of the total body K+ content (2500–4500 mmol). The ratio 
of ICF to ECF K+ concentration (normally 38:1) is the principal result of the 
resting membrane potential and is crucial for normal neuromuscular 
function. The basolateral Na+, K+-ATPase pump actively transports K+ in 
and Na+ out of the cell in a 2:3 ratio, and the passive outward diffusion of K+ 
is quantitatively the most important factor that generates the resting 
membrane potential. The activity of the electrogenic Na+, K+-ATPase pump 
may be stimulated as a result of an increased intracellular Na+ concentration 
and inhibited in the setting of digoxin toxicity or chronic illness such as 
heart failure or renal failure12. 
                           The K+ intake of individuals on an average western diet is 
40–120 mmol/d, or approximately 1 mmol/kg per day, 90% of which is 
absorbed by the gastrointestinal tract. Maintenance of the steady state 
necessitates matching K+ ingestion with excretion. Initially, extrarenal 
adaptive mechanisms, followed later by urinary excretion, prevent a 
doubling of the plasma K+ concentration that would occur if the dietary K+ 
load remained in the ECF compartment. Immediately following a meal, most 
of the absorbed K+ enters cells as a result of the initial elevation in the 
plasma K+ concentration and facilitated by insulin release and basal 
catecholamine levels. Eventually, however, the excess K+ is excreted in the 
urine. The regulation of gastrointestinal K+ handling is not well understood. 
The amount of K+ lost in the stool can increase from 10 to 50% or 60% (of 
dietary intake) in chronic renal insufficiency. In addition, colonic secretion 
of K+ is stimulated in patients with large volumes of diarrhea, resulting in 
potentially severe K+ depletion.12 
Hypokalemia 
                      Hypokalemia is defined as a plasma K+ concentration <3.5 
mmol/L12 Hypokalemia is often associated with acid-base disturbances 
related to the underlying disorder. In addition, K+ depletion results in 
intracellular acidification and an increase in net acid excretion or new 
HCO3– production. This is a consequence of enhanced proximal HCO3– 
reabsorption, increased renal ammoniagenesis, and increased distal H+ 
secretion. This contributes to the generation of metabolic alkalosis 
frequently present in hypokalemic patients. NDI  is not uncommonly seen in 
K+ depletion and is manifest as polydipsia and polyuria. Glucose intolerance 
may also occur with hypokalemia and has been attributed to either impaired 
insulin secretion or peripheral insulin resistance12. 
Clinical Findings: 
Symptoms and Signs: 
                                     Muscular weakness, fatigue, and muscle cramps are 
frequent complaints in mild to moderate hypokalemia. Smooth muscle 
involvement may result in constipation or ileus. Flaccid paralysis, 
hyporeflexia, hypercapnia, tetany, and rhabdomyolysis may be seen with 
severe hypokalemia (< 2.5 mEq/L). The presence of hypertension may serve 
as a clue to the diagnosis of hypokalemia from aldosterone or 
mineralcorticoid excess13 . 
Laboratory Findings  
                                     Urinary potassium concentration is low (< 20 mEq/L) 
as a result of extrarenal fluid loss (eg, diarrhea, vomiting) and 
inappropriately high (> 40 mEq/L) with urinary losses  
                  Hypokalemia with a The transtubular [K+] gradient (TTKG)  > 4 
suggests renal potassium loss with increased distal K+ secretion. In such 
cases, plasma renin and aldosterone levels are helpful in differential 
diagnosis. The presence of nonabsorbed anions, including bicarbonate, also 
increases TTKG13,15. 
                 Loop diuretics may cause hypomagnesemia as well as 
hypokalemia13.  
                   The electrocardiographic changes of hypokalemia are due to 
delayed ventricular repolarization and do not correlate well with the plasma 
K+ concentration12. The electrocardiogram (ECG) shows decreased 
amplitude and broadening of T waves, prominent U waves, premature 
ventricular contractions, and depressed ST segments13,16. 
Hyperkalemia 
                      Hyperkalemia, defined as a plasma K+ concentration >5.0 
mmol/L12, occurs as a result of either K+ release from cells or decreased 
renal loss. Clinical Features Since the resting membrane potential is related 
to the ratio of the ICF to ECF K+ concentration, hyperkalemia partially 
depolarizes the cell membrane. Prolonged depolarization impairs membrane 
excitability and is manifest as weakness, which may progress to flaccid 
paralysis and hypoventilation if the respiratory muscles are involved. 
Hyperkalemia also inhibits renal ammoniagenesis and reabsorption of NH4+ 
in the TALH. Thus, net acid excretion is impaired and results in metabolic 
acidosis, which may further exacerbate the hyperkalemia due to K+ 
movement out of cells12.  
                      The most serious effect of hyperkalemia is cardiac toxicity, 
which does not correlate well with the plasma K+ concentration. The earliest 
electrocardiographic changes include increased T-wave amplitude, or 
peaked T waves. More severe degrees of hyperkalemia result in a prolonged 
PR interval and QRS duration, atrioventricular conduction delay, and loss of 
P waves. Progressive widening of the QRS complex and merging with the T 
wave produces a sine wave pattern. The terminal event is usually ventricular 
fibrillation or asystole12,17. 
Fluid and Electrolyte Disorders in HIV infected patients 
Disorders of Osmolality 
                                       Hyponatremia is a frequent finding among HIV-
infected persons, with a reported prevalence of 30-60% in hospitalized 
patients18,19.  
                      It is a marker of severe illness that is associated with increased 
mortality in HIV-infected patients20. In a study  of 96 consecutive patients 
with acquired immune deficiency syndrome (AIDS) or AIDS-related 
complex (ARC) conducted in Department of Medicine, Long Island Jewish 
Medical Center, New Hyde Park 11042, 31.3%  patients had hyponatremia. 
The probability of 50% survival after diagnosis of human immunodeficiency 
virus (HIV) infection in the hyponatremic group was 11.5 months, as 
compared to 39 months for those without hyponatremia, p less than 0.001. 
Hyponatremia occurs commonly in ambulatory patients with ARC or AIDS, 
appears in patients with higher mortality and morbidity, and does not 
represent a terminal event. Most patients had hypovolemia and unexpectedly 
high urine sodium concentration, suggesting defective renal sodium 
conservation20.        In another study of 212 HIV-infected patients admitted 
to a large metropolitan hospital, the mortality rate for the hyponatremic 
group was higher than that for the normonatremic group                                                
(36.5% vs 19.7%; p < .01) 21.  
 
                            In one study, Burton D Rose et al found that Hyponatremia 
and hyperkalemia are the two major electrolyte disorders that may be 
associated with HIV infection38. In addition, lactic acidosis, hyperuricemia, 
and hypophosphatemia have been described38.  And they have found that the 
incidence of hyponatremia in hospitalized HIV-infected patients has been 
reported to be between 35 and 55 percent. In one prospective analysis of 167 
patients with AIDS and 45 patients with ARC admitted on 269 occasions to 
a large metropolitan teaching hospital during a 3-month period showed 
Eighty-three patients (39%) had hyponatremia .Hyponatremia was present 
on admission during 57 hospitalizations and was associated with 
gastrointestinal losses and hypovolemia in 43%. When hyponatremia 
developed during hospitalisation, 68% of the patients were clinically 
euvolemic and had a syndrome consistent with inappropriate secretion of 
antidiuretic hormone (SIADH) 22.  
                            The etiology and management of hyponatremia may differ 
according to the timing of its presentation. Volume depletion caused by 
diarrhea or vomiting is the usual cause of hyponatremia present at the time 
of hospital admission. Clinical management includes replacement of the 
volume deficit, along with measures to treat the underlying cause of volume 
depletion. In contrast, the syndrome of inappropriate antidiuretic hormone 
(SIADH) is the likely culprit among patients who develop hyponatremia 
during hospitalization18. SIADH is associated with common pulmonary and 
intracranial diseases such as Pneumocystis jiroveci pneumonia, 
toxoplasmosis, and tuberculosis. The initial treatment of SIADH consists of 
fluid restriction and treatment of the underlying infection or malignancy. 
Persistent release of antidiuretic hormone resulting from infections that are 
slow to respond to treatment also can be managed with demeclocycline at a 
dosage of 600-1,200 mg per day, which will inhibit the action of antidiuretic 
hormone on the renal tubule23 
 
 
Potassium Disorders 
                                     Both hypokalemia and hyperkalemia are common 
among HIV-infected patients. Hypokalemia is usually found in the setting of 
gastrointestinal infections leading to vomiting or diarrhea. Amphotericin B, 
frequently used to treat fungal infections in patients with AIDS, can cause 
tubular dysfunction resulting in hypokalemia. As noted, tenofovir has been 
associated with proximal tubular dysfunction resulting in an electrolyte 
wasting state, including life-threatening hypokalemia24,25,26 
                      Drug-induced hyperkalemia is common among patients 
receiving either high-dose trimethoprim-sulfamethoxazole or intravenous 
pentamidine. In a manner similar to the action of potassium-sparing diuretics 
such as amiloride, both drugs inhibit distal nephron sodium transport, 
leading to a decrease in potassium secretion27,28. Hyperkalemia and 
hyponatremia also may be a manifestation of mineralocorticoid deficiency 
resulting from adrenal insufficiency or the syndrome of hyporeninemic 
hypoaldosteronism29,30.Acute or chronic kidney disease also may contribute 
to potassium retention. Adrenal causes of hyperkalemia often respond 
clinically to treatment of the underlying disorder, loop diuretics, or 
fludrocortisone.30       
Acid-Base Disorders 
                                                 Acid-base disturbances in HIV-infected 
patients are commonly caused by infections or drugs. Respiratory alkalosis 
and respiratory acidosis may occur in opportunistic infections of the lungs or 
central nervous system. Non anion gap metabolic acidosis may occur as a 
result of several different processes, including intestinal losses of bases 
caused by diarrhea and renal acidosis resulting from adrenal insufficiency, 
the syndrome of hyporeninemic hypoaldosteronism, or drug toxicity (eg, 
amphotericin B) 31,29,32.  
                                   High anion gap metabolic acidosis in this population 
results from chronic kidney disease, type A lactic acidosis caused by tissue 
hypoxia, and type B lactic acidosis33.Type B lactic acidosis presents with 
markedly elevated blood lactate levels, possibly caused by drug-induced 
mitochondrial dysfunction. Affected patients show no evidence of 
hypoxemia, tissue hypoperfusion, malignancy, or sepsis. This disorder has 
been reported with use of nucleoside reverse transcriptase inhibitors such as 
zidovudine, didanosine, zalcitabine, lamivudine, and stavudine34. Although 
life-threatening acidosis is rare, 5-25% of treated patients may develop 
mildly elevated lactate levels (2.5-5 mmol/L) without acidosis. The value of 
screening and the predictive value of small, asymptomatic elevations in 
lactate are unknown34,35. Routine monitoring for hyperlactatemia with lactic 
acid levels is not recommended, but lactic acid levels should be measured in 
patients who present with low bicarbonate levels, an elevated anion gap, or 
abnormal liver enzymes36.  
Other less common electrolyte disturbances37 
1. hypocalcemia 
2. hypercalcemia 
3. hypourecemia 
4. hyperuricemia 
5. lactic acidosis 
6. hypophosphatemia 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY 
1) To find out the prevalence of electrolyte disturbances in HIV infected 
patients 
2) And their correlation with CD4+ counts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
Study design : Cross sectional study 
Study Population: 
                           The cross sectional study included all 150 patients 
admitted in medicine and STD wards, GRH. Both male and female patients 
were included in this study  
 
Place : Medicine Dept., 
           Govt. Rajaji Hospital,  
           Madurai Medical College, 
           Madurai. 
Collaborative Departments: 1) Department of Bio-Chemistry, 
                                                     Govt. Rajaji Hospital,  
                                                     Madurai Medical  College, 
                                                     Madurai.    
                                                    2)  Department of STD, 
                                                     Govt. Rajaji  Hospital, 
                                                     Madurai Medical  College,  
                                                     Madurai.                                                                                               
                                                                                                                                                                                                                                                            
Period of study: 6 months (Nov 1,2008 to April 30, 2009). 
Sample size: 150 patients. 
Selection of the study subjects:  
                                                    150 patients admitted with HIV infection in 
the medical and STD wards, Govt. Rajaji Hospital from July to December 
2008 formed the study group.  
 
                              All patient’s with HIV infection, admitted in both 
medical and dept. of STD are included in this study which includes both 
AIDS related complex and AIDS. Since only symptomatic patients and 
patients with opportunistic infections(eg. T.B meningitis, chronic diarrhea, 
etc., ) are getting admitted in wards, asymptomatic patients were not 
included in this study.   
 
                               111 male and 39 female patients were included in this 
study. Sex distribution is shown in table 1. 
 
 
 
TABLE 1)SEX DISTRIBUTION 
 FREQUENCY PERCENT 
FEMALE 39 26.0 
MALE 111 74.0 
VALID 
TOTAL 150 100.0 
 
 
                                 Most patients were newly detected and some patients 
received anti retro viral therapy. Separation was not done. All 150 patients 
were HIV-1 positive for ELISA (Enzyme Linked Immuno Sorbant Assay). 
Test repeated and confirmed for all patients. WESTERN BLOT could not 
be performed because of limited resources.  
 
                                Tests for CD4+ count, blood sugar, blood urea, serum 
creatinine, Serum sodium, serum potassium done for all patients and were 
recorded properly. CD4+ count was done using flow cytometry. It was  
measured in  Cells/µL. Blood sugar, blood urea, serum creatinine, Serum 
sodium, serum potassium are done by using automated analyzer. 
 BUN (Blood Urea Nitrogen) values were calculated by using formula 
(BUN=blood urea/2.13). Since impaired renal function itself can alter the 
serum electrolytes, patients with elevated renal parameters were not 
included in this study. Patients with symptomatic and asymptomatic 
electrolyte disturbances were not grouped.  
                               
                               The etiology of the electrolyte disturbances could not be 
found out because of limited resources. 
 
Consent: Informed consent was obtained 
Ethical committee approval: Obtained 
Financial support: Nil 
Conflict of interest: Nil 
Statistical tool used:  
                               The information collected regarding all the 
selected cases were recorded in a Master Chart. Data analysis was done with 
the help of computer using SPSS version 13. 
  
                      Using this software range, frequencies, percentages, 
means, standard deviations, chi square and  'p'  values were calculated. 
Kruskul Wallis chi-square test was used to test the significance of difference 
between quantitative variables. A 'p' value less than 0.05 is taken to denote 
significant relationship. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 
 
 
 
 
 
 
FIGURE 2 
 
 
 
 
 
 
 FIGURE 3 
 
 
 
 
 
 
 FIGURE 4) SEX DISTRIBUTUON OF SERUM SODIUM  LEVELS 
 
 
 
 
 
 
 
 
  
 
 
FIGURE 5) SEX DISTRIBUTUON OF SERUM POTASSIUM 
LEVELS 
 
 
 
 
FIGURE 6) FREQUENCY DISTRIBUTUON OF SERUM SODIUM 
LEVELS 
 
 
 
 
 
 
 
 
FIGURE 7) FREQUENCY DISTRIBUTUON OF SERUM 
POTASSIUM LEVELS 
 
 
 
 
 
 
 RESULTS AND ANALYSIS 
 
                  The results obtained from this present study as shown in table 2. 
TABLE 2 
 AGE 
CD4 
COUNT 
BLOOD 
SUGAR 
BLOOD 
UREA 
NITROGEN 
CREATIN
INE 
SERU
M 
SODI
UM 
SERUM 
POTASSIU
M 
N VALID 150 150 150 150 150 150 150 
  MISSIN
G 
0 0 0 0 0 0 0 
MEAN 
30.85 209.4533 
78.280
0 
16.3943 .99867 
136.6
533 
4.010 
STD. 
DEVIATION 
4.781 80.88019 
15.455
12 
1.83796 .138538 
6.003
34 
.9556 
MINIMUM 
24 75.00 60.00 12.67 .600 
125.0
0 
2.5 
MAXIMUM 
39 349.00 100.00 20.00 1.200 
146.0
0 
7.4 
 
                              It indicate  the mean age is 30.85 ± 4.78 (±1SD). The 
minimum and maximum CD4+ counts are  75, 349/micro litre respectively. 
The mean CD4 count is 209.45±80.88/micro litre (±1SD).The mean serum 
sodium level is 136.65±6.00(±1SD)Meq/litre. The minimum and maximum 
serum sodium level  are  125 Meq/litre,146 Meq/litre respectively (Figure 6) 
(Table 1).The mean serum potassium levels is4.01±0.95 Meq/litre (±1SD). 
The minimum and maximum serum potassium levels  observed are  2.5 
Meq/litre,7.4 Meq/litre respectively (table 2) (Figure 7). 
 
                                   Among 150 pt’s, 52 pt’s had hyponatremia and 98 
patients had normal  sodium levels (Figure2). The percentage of 
hyponatremia is 34.7%. Among the 52 patients, female patients are 32 and 
males are 20 . And the percentage of hyponatremia for both males and 
females are 14.7%, 20.0% respectively (table 3) (Figure 4). 
 
 
 
 
 
 
TABLE 3)DISTRIBUTION OF SERUM SODIUM LEVEL 
 
 FREQUENCY PERCENT 
<=134(HYPONATRE
MIA) 
52 34.7 
135-150 (NORMAL) 98 65.3 
VALID 
TOTAL 150 100.0 
 
                        
 
                                There is a significant correlation between serum sodium 
levels and CD4+ cell count (Pearson correlation is 0.622). Correlation is 
significant at the 0.01 level (2-tailed) (table 4). 
 
 
 
 
 
TABLE 4)CORRELATIONS BETWEEN CD4 COUNT AND SERUM SODIUM 
LEVEL 
 
  
CD4 COUNT SERUM SODIUM 
PEARSON CORRELATION 1 .622(**) 
SIG. (2-TAILED)   .000 
CD4 COUNT 
  
  N 150 150 
PEARSON CORRELATION .622(**) 1 
SIG. (2-TAILED) .000   
SERUM SODIUM 
  
  N 150 150 
                                  
                                     **  CORRELATION IS SIGNIFICANT AT THE 0.01 LEVEL (2-
TAILED). 
 
 
 
                 Relationship between Serum Sodium and CD4 Count is shown in 
table 5. 
 
 TABLE NO 5 : RELATIONSHIP BETWEEN SERUM SODIUM AND CD4 COUNT 
 
  
SERUM SODIUM N MEAN 
STD. 
DEVIATION 
T TEST (P 
VALUE) 
CD4 
COUNT 
<=134(HYPONATR
EMIA) 
52 128.5577 40.65320 
  135-150 
(NORMAL) 
98 252.3776 61.72395 
0.000*** 
 
 
        
                  Among 150 pt’s, 28 pt’s had hypokalemia and 108 patients had 
normal potassium levels, 14 patients had hyper kalemia (Figure 3). The 
percentage of hypokalemia is 18.7%. the percentage of normal potassium 
level is 72.0%. The percentage of hyperkalemia is 9.3% (table 6) (Figure 3).  
 
 
 
 
TABLE 6)DISTRIBUTION OF SERUM POTASSIUM LEVEL 
 
 FREQUENCY PERCENT 
<=3.4(HYPOKALEMI
A) 
28 18.7 
3.5-5.0 (NORMAL) 108 72.0 
>=5.1(HYPERKAEMI
A) 
14 9.3 
VALID 
TOTAL 150 100.0 
 
 
 
                     All patients with Hypokalemia are males (figure 5). Among 
108 patients with normal potassium levels female and male patients are 34 , 
74 respectively(figure 5), with the percentage of  22.7% and 49.3% 
respectively. Among 14 patients with hyperkalemia  9 patients are males and 
5 patients are females, with the percentage of  6.0% and 3.3% 
respectively(figure 5).There is no significant correlation between serum 
potassium levels and CD4+ cell count (Pearson correlation is 0.058) (table 
7). 
 TABLE 7 
Correlation Between Serum Potassium And CD4 Count
1 .058
.479
150 150
.058 1
.479
150 150
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
CD4 count
Serum Potassium
CD4 count
Serum
Potassium
 
 
  
 
                   Relationship Between Cd4 Count and Serum Potassium Level 
By ANOVA is shown in table 8. 
                       
 
 
 
 
 
 TABLE 8) RELATIONSHIP BETWEEN CD4 COUNT AND SERUM POTASSIUM 
LEVEL BY ANOVA 
 
CD4 COUNT  
  
SUM OF 
SQUARES DF MEAN SQUARE F SIG. 
BETWEEN K+ 
CATEGORIES 
12980.861 2 6490.431 
WITHIN K+ 
CATEGORIES 
961718.312 147 6542.301 
TOTAL 974699.173 149   
.992 
  
  
.373 
  
  
 
 
 
 
 
 
 
 
 
 DISCUSSION 
                       
                            Hyponatremia, hypokalemia and hyperkalemia are 
common electrolyte disorders with HIV infected patients. I describe here a 
high incidence of electrolyte disorders among HIV infected patients 
admitted in Govt. Rajaji Hospital, Madurai. Numerous factors might have 
contributed to such high rates of electrolyte disturbances.  
              Among 150 patients, 52 patients had hyponatremia. The percentage 
of hypo natremia is 34.7%.  
          The high incidence of hyponatremia may be due to 
1. volume depletion caused by diarrhea or                                    
vomiting18 
2. persistent release of antidiuretic hormone 
resulting from infections23  
3. the syndrome of inappropriate antidiuretic 
hormone (SIADH) 18. 
                 Persistent vomiting, and the the syndrome of inappropriate 
antidiuretic hormone (SIADH) will cause hypo osmolar hyponatremia. But 
in SIADH the volume status will be euvolemic12.  
                  In one study, Burton D Rose et al found that Hyponatremia and 
hyperkalemia are the two major electrolyte disorders that may be associated 
with HIV infection38. In addition, lactic acidosis, hyperuricemia, and 
hypophosphatemia have been described38.  And they have found that the 
incidence of hyponatremia in hospitalized HIV-infected patients has been 
reported to be between 35 and 55 percent. The results were comparable to 
this study. 
                    SIADH in HIV infection may be associated with common 
pulmonary and intracranial diseases such as Pneumocystis jiroveci 
pneumonia, toxoplasmosis, and tuberculosis, since most of the patients were 
admitted for their opportunistic infections.  
   SIADH is diagnosed by confirming 
                                    (a) a hypo-osmotic hyponatremia,  
                                   (b) an inappropriately concentrated urine (urine    
                                     osmolality >100 mOsm/L),                                                                                                                                                                                                           
                                  (c) euvolemia, and  
                                  (d) An absence of adrenal, and thyroid dysfunction or 
other conditions associated with increased ADH action.  
                Hyponatremia due to volume depletion caused by diarrhea or 
vomiting can be distinguished from the SIADH by the low urine sodium 
concentration (usually below 15 meq/L) and correction of the hyponatremia 
with fluid repletion38. Defective renal sodium conservation due to HIV 
infection of the kidney it self can cause hyponatremia20. 
                There is a significant correlation between serum sodium levels and 
CD4+ cell counts (Pearson correlation is 0.622). Correlation is significant at 
the 0.01 level (2-tailed) .This is probably because that the opportunistic 
infections are more common with lower  CD4+ cell counts. 
              Among 150 pt’s, 28 pt’s had hypokalemia and 108 patients had 
normal potassium levels, 14 patients had hyper kalemia (Figure 3). The 
percentage of hypokalemia is 18.7%. The percentage of normal potassium 
level is 72.0%.The percentage of hyperkalemia is 9.3%. Both hypokalemia 
and hyperkalemia are common with HIV infection. In this study 
Hypokalemia(18.7%) more common than hyperkalemia(9.3%). There is no 
significant correlation between serum potassium levels and CD4+ cell count 
(Pearson correlation is 0.058) (table 3). 
                Hypokalemia  may be because of gastrointestinal infections 
causing vomiting or diarrhea24,25,26. Amphotericin B, frequently used to treat 
fungal infections in patients with AIDS, can cause tubular dysfunction 
resulting in hypokalemia. Tenofovir has been associated with proximal 
tubular dysfunction resulting in an electrolyte wasting state, including life-
threatening Hypokalemia.24,25,26                               
                              Drug-induced hyperkalemia is common among patients 
receiving either high-dose trimethoprim-sulfamethoxazole or intravenous 
pentamidine27,28. In a manner similar to the action of potassium-sparing 
diuretics such as amiloride, both drugs inhibit distal nephron sodium 
transport, leading to a decrease in potassium secretion27,28. Hyperkalemia 
and hyponatremia also may be a manifestation of mineralocorticoid 
deficiency resulting from adrenal insufficiency or the syndrome of 
hyporeninemic hypoaldosteronism29,30. Adrenal causes of hyperkalemia 
often respond clinically to treatment of the underlying disorder, loop 
diuretics, or fludrocortisone30            
                          This study does have certain limitations, including a limited 
sample size. The etiology of the electrolyte disturbances were not identified 
because of limited resources.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
                         Hyponatremia, hypokalemia and hyperkalemia are common 
electrolyte disorders with HIV infected patients. Because of the high 
incidence of the electrolyte disturbances with HIV infected patients, close 
monitoring and aggressive management are mandatory. 
 
 
 
 
 
 
 
 
 
APPENDIX 
ABBREVIATIONS 
HIV- HUMAN IMMUNODEFICIENCY VIRUS 
AIDS- AQUIRED IMMUNO DEFICIENCY SYNDROME 
SIADH- SYNDROME  OF INAPPROPRIATE ANTI DIURETIC HARMONE        
SECRETION  
ELISA- ENZYME LINKED IMMUNO SORBANT ASSAY 
RT-PCR- REAL TIME POLYMERASE CHAIN REACTION 
CD- CLUSTER OF DIFFERENTIATION 
HTLV- HUMAN T CELL LYMPHOTROPHIC VIRUS 
TALH- THICK ASCENDING LOOP OF HENLE  
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Electrolyte disturbances in HIV infected patients 
Proforma 
 
Name:                                                                             Age/sex:           
 
 
 Ip.No:                                                                             Date: 
 
HIV infection status: 
 
Duration of HIV positivity:  
                                
CD4 count:                               /microlitre.                    CD4 %: 
  
 H/o ART:   Yes/No, If yes duration: 
 
Opportunistic infections: Present/Not present. 
 
                                          If present, details:  
 
                            
Clinical details: 
 
                  Volume status: hypovolemia/euvolemia/volume overload 
 
                  Anorexia/nausea/Vomiting/diarrhea/confusion/ 
 
head ache/lethargy/convulsion/ coma/muscle cramps/tetany/weakness  
                      
H/o any other drug intake: Yes /  No, 
 
                                              If yes details: 
 
 
                 BP:         /         mmHg.  Pulse:          /min.  Urine output:                 ml/day. 
 
Laboratory Data: 
 
            Bl.sug:            mg/dl. Blood urea nitrogen:           mg/dl. 
 
                Serum creatinine:            mg/dl  
              
                Serum Na+:         mmol/l.          Serum K+:          mmol/l.  
                             
                Sr.Cl-:             mmol/l.                                      Sr.HCO3-:            mmol/l. 
 
                Calculated serum osmolarity:                mmol/l. 
 
                Spot urine Na:            mmol/l.  
 
                Calculated urine osmolarity:                mmol/l.  
 
Summary:                                                                      
 
 
MASTER CHART 
S.No Age Sex 
CD4 
count 
  Sug BUN Creatinine 
                       
Sr.Electrolytes 
    
                Sr.Na+ Sr.K+   
1 31 M 160  69 18 1 131 4.8  
2 32 M 120  71 17 1.2 131 3.2  
3 27 F 75  100 14.08 0.9 125 3.8  
4 34 M 240  63 16 1.1 140 4.9  
5 32 M 200  98 19 1 144 3.5  
6 37 M 310  60 16 1.1 141 4.4  
7 26 M 320  70 18.03 1.1 138 3.8  
8 31 M 160  69 18 1 131 6  
9 27 F 75  100 14.08 0.9 126 3.8  
10 35 M 208  63 16 1.1 140 4.9  
11 35 M 179  95 15 0.9 146 3.5  
12 28 M 349  70 12.67 1.2 142 3.6  
13 26 F 80  97 14.08 0.7 128 6.2  
14 34 M 240  63 16 1.1 140 4.1  
15 39 M 155  66 18 1 131 5  
16 37 M 310  60 16 1.1 141 4.9  
17 33 M 184  95 18 0.9 146 3.5  
18 24 M 290  73 17 1.1 137 6.5  
19 37 M 310  60 16 1.1 141 4.4  
20 33 M 184  95 18 0.9 146 3.5  
21 34 M 240  63 16 1.1 140 4.9  
22 30 M 208  98 17 1 144 6.9  
23 29 M 320  70 16 1.1 138 3.8  
24 28 F 84  97 14.08 0.6 127 3.8  
25 24 M 290  73 17 1.1 137 3.8  
26 35 M 208  63 16 1.1 140 3.2  
27 32 M 120  71 17 1.2 131 3.2  
28 26 F 80  97 14.08 0.7 128 3.8  
29 39 F 155  66 18 1 131 5  
30 33 M 184  95 18 0.9 146 3.5  
31 24 M 290  73 17 1.1 137 6.1  
32 36 M 164  69 18 1 131 4  
33 24 F 175  100 14.08 0.8 129 3.8  
34 30 M 208  98 17 1 144 3.5  
35 29 M 320  70 16 1.1 138 3.8  
36 26 F 80  97 14.08 0.7 128 3.8  
37 39 M 155  66 18 1 134 2.9  
38 28 F 84  97 14.08 0.6 128 3.8  
39 37 M 165  66 18 1 137 3.2  
40 37 M 165  66 18 1 137 3.2  
41 37 M 320  60 16 1.1 141 4.7  
42 32 M 200  98 17 1 144 3.5  
43 37 M 320  60 16 1.1 141 4.7  
44 37 M 310  60 16 1.1 141 3.2  
45 32 M 200  98 17 1 144 3.5  
46 24 F 175  100 14.08 0.9 125 3.8  
47 35 M 179  95 15 0.9 146 3.5  
48 28 M 349  70 12.67 1.2 142 3.6  
49 24 M 290  73 20 1.1 137 6.4  
50 25 M 209  67 19 1 135 3.6  
51 31 M 160  69 18 1 131 3.8  
52 27 F 75  100 14.08 0.9 127 7.4  
53 32 M 200  98 19 1 144 3.5  
54 26 M 320  70 18.03 1.1 138 3.8  
55 32 M 200  98 19 1 144 3.5  
56 26 M 320  70 18.03 1.1 138 6.9  
57 26 F 80  97 14.08 0.7 128 3.8  
58 39 M 155  66 18 1 131 2.9  
59 33 M 184  95 18 0.9 146 3.5  
60 37 M 310  60 16 1.1 141 4.9  
61 34 F 240  63 16 1.1 140 4.1  
62 24 F 290  73 20 1.1 137 4.8  
63 25 M 209  67 19 1 135 3.6  
64 25 M 209  67 19 1 135 3.6  
65 28 M 349  70 12.67 1.2 142 3.6  
66 24 F 175  100 14.08 0.9 129 3.8  
67 37 M 310  60 16 1.1 141 3.2  
68 32 M 200  98 17 1 144 3.5  
69 37 M 310  60 16 1.1 141 3.2  
70 28 F 84  97 14.08 0.6 128 3.8  
71 24 F 175  100 14.08 0.8 129 5.8  
72 30 M 208  98 17 1 144 3.5  
73 36 M 164  69 18 1 130 3.2  
74 28 M 349  70 12.67 0.9 142 3.6  
75 32 M 120  71 17 1.2 131 3.2  
76 24 F 175  100 14.08 0.8 129 3.8  
77 29 M 320  70 16 1.1 138 3.8  
78 25 F 159  81 15.49 1 135 3.5  
79 24 F 175  100 14.08 0.9 129 3.8  
80 24 M 290  73 17 1.1 137 3.8  
81 31 M 160  69 18 1 131 6.4  
82 27 F 75  100 14.08 0.9 129 3.8  
83 32 M 200  98 19 1 144 3.5  
84 35 M 208  63 16 1.1 140 3.2  
85 28 M 349  70 12.67 0.9 142 3.6  
86 26 F 320  70 18.03 1.1 138 3.8  
87 35 M 208  63 16 1.1 140 4.9  
88 36 M 164  69 18 1 131 4  
89 32 M 120  71 17 1.2 130 3.2  
90 37 M 165  66 18 1 137 2.7  
91 37 M 320  60 16 1.1 141 3.2  
92 24 F 175  100 14.08 0.8 129 3.8  
93 29 M 320  70 16 1.1 138 3.8  
94 25 F 159  81 15.49 1 135 3.5  
95 37 M 165  66 18 1 137 2.7  
96 37 M 320  60 16 1.1 141 3.2  
97 35 M 179  95 15 0.9 146 3.5  
98 24 F 290  73 20 1.1 137 3.8  
99 35 M 179  95 15 0.9 146 3.5  
100 24 M 290  73 20 1.1 137 3.8  
101 36 M 164  69 18 1 131 3.2  
102 30 M 208  98 17 1 144 3.5  
103 28 F 84  97 14.08 0.6 128 3.8  
104 32 M 200  98 17 1 144 3.5  
105 37 M 310  60 16 1.1 141 3.2  
106 24 F 175  100 14.08 0.9 129 3.8  
107 28 M 349  70 12.67 1.2 142 3.6  
108 25 M 209  67 19 1 135 3.6  
109 31 M 160  69 18 1 131 4.8  
110 32 M 120  71 17 1.2 131 3.2  
111 27 F 75  100 14.08 0.9 129 3.8  
112 34 M 240  63 16 1.1 140 4.9  
113 32 M 200  98 19 1 144 3.5  
114 37 M 310  60 16 1.1 141 4.4  
115 26 M 320  70 18.03 1.1 138 3.8  
116 31 M 160  69 18 1 131 3.8  
117 27 F 75  100 14.08 0.9 129 6.2  
118 35 M 208  63 16 1.1 140 4.9  
119 37 F 310  60 16 1.1 141 4.4  
120 33 M 184  95 18 0.9 146 3.5  
121 34 M 240  63 16 1.1 140 4.9  
122 30 M 208  98 17 1 144 6.4  
123 29 M 320  70 16 1.1 138 3.8  
124 28 F 84  97 14.08 0.6 128 3.8  
125 24 M 290  73 17 1.1 137 3.8  
126 35 M 208  63 16 1.1 140 3.2  
127 32 M 120  71 17 1.2 131 3.2  
128 26 F 80  97 14.08 0.7 128 3.8  
129 39 M 155  66 18 1 134 2.9  
130 28 F 84  97 14.08 0.6 128 3.8  
131 37 M 165  66 18 1 137 3.2  
132 37 M 165  66 18 1 137 3.2  
133 37 M 320  60 16 1.1 141 4.7  
134 32 M 200  98 17 1 144 3.5  
135 37 M 320  60 16 1.1 141 4.7  
136 37 M 310  60 16 1.1 141 3.2  
137 32 M 200  98 17 1 144 3.5  
138 24 F 175  100 14.08 0.9 129 3.8  
139 26 F 80  97 14.08 0.7 126 3.8  
140 39 M 155  66 18 1 131 2.5  
141 33 F 184  95 18 0.9 146 3.5  
142 37 M 310  60 16 1.1 141 4.9  
143 34 M 240  63 16 1.1 140 4.1  
143 24 M 290  73 20 1.1 137 3.8  
145 25 F 209  67 19 1 135 7  
146 25 M 209  67 19 1 135 3.6  
147 28 M 349  70 12.67 1.2 142 3.6  
148 24 F 175  100 14.08 0.9 129 3.8  
149 31 M 160  69 18 1 131 3.8  
150 27 F 75  100 14.08 0.9 129 6.2  
           
 
 
